培门冬酶联合化疗治疗T细胞淋巴瘤的疗效和安全性分析

Analysis of the efficacy and safety of Pegaspargase combined with chemotherapy in the treatment of T-cell lymphoma

目的观察培门冬酶(PEG-ASP)与化疗联合治疗T细胞淋巴瘤的临床疗效和不良反应。方法回顾性分析2011年1月至2015年7月应用培门冬酶联合化疗治疗的35例T细胞淋巴瘤患者的临床资料,评价培门冬酶的临床疗效和不良反应。结果 35例患者总的治疗有效率为74.3%(26/35),完全缓解率为34.3%(12/35),部分缓解率为40.0%(14/35);2年总生存率77.1%。不良反应主要为胃肠道反应42.9%(15/35),骨髓抑制25.7%(9/35),凝血异常8.6%(3/35),药物性肝炎8.6%(3/35),无过敏反应、胰腺炎及血栓的发生。结论 PEG-ASP联合化疗治疗T细胞淋巴瘤的临床疗效较好,不良反应可以耐受,值得临床进一步推广应用。

Objective To observe the clinical effects and side effects of Pegaspargase combined with chemotherapy in the treatment of T-cell lymphoma.Methods The clinical data of 35T-cell lymphoma patients on PEG-ASP-based chemotherapy from January 2011 to July 2015 were retrospectively collected and analyzed.Results The overall response rate was 74.3%(26/35).And complete remission was 34.3%(12/35)and partial remission 40.0%(14/35).Two-year overall survival rate was 77.1%.The common adverses included gastrointestinal(n=15,42.9%),myelosuppression(n=9,25.7%),coagulopathy(n=3,8.6%),liver damage(n=3,8.6%).No instance of anaphylaxis,pancreatitis and thrombosis occurred.Conclusion PEG-ASP combined with chemotherapy in the treatment of T-cell lymphoma is efficacy and safety,which is worthy of further clinical application.